Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study

Study Overview
=================
Brief Summary
-----------------
This is a multicenter, 1-year prospective, observational study of Atrial Fibrillation (AF) in Greece, designed to provide real world data regarding the characteristics of AF patients in Greece, as well as current clinical practices and adherence to the 2010 ESC guidelines.

Official Title
-----------------
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study

Conditions
-----------------
Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged ≥ 18 years with any type of AF(first diagnosed, paroxysmal, persistent, long-standing persistent and permanent) according to the classification described in the recent ESC guidelines. All patients should give written informed consent to participate in the study. Exclusion Criteria: Patients anticipated life expectancy less than 1 year due to a severe concomitant disease. Participation in an another clinical trial, with the exception of epidemiology trials (observational) that do not influence AF management. Patients with mental disability unable to comply with follow - up visits and these who are unable to provide, in written, their informed consent or patients with anticipated inability to adhere to scheduled follow up visits.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the management of patients with Atrial Fibrillation. | Evaluation of the use of anticoagulants and antithrombotic drugs. Evaluation of the doctors' compliance with the guidelines. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the risk of strokes. | Evaluation of the risk in a large number of patients using the CHA2DS2-VASc and HAS-BLED scores. | Baseline-6month-12months | 
| Assessment of morbidity and mortality of patients with AF. | Assessment of morbidity and mortality of patients with AFduring one year follow-up in comparison with previous results from other registries. | 1 year | 
| Assessment of the compliance of patients to treatment. | Evaluation of the compliance of patients to treatment and the frequency of visits to their physician especially in terms of achieving therapeutic target INR (TTR, Time in Therapeutic Range). | Baseline-6months-12months | 
| Assessment of the awareness of patients about the Atrial Fibrillation. | Assessment of the awareness of patients about the Atrial Fibrilation and the potential risk of AF. | Baseline | 
| Assessment of patients' quality of life. | Assessment of patients' quality of life (QoL) using a specific questionnaire (EQ - 5D, http://www.euroqol.org) and EHRA score for evaluation of symptoms. | Baseline-6months-12months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atrial Fibrillation, AF